Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis

GLIA

Volumn 57, Issue 2, 2009, Pages 182-193

  Paintlia, Ajaib S ^a   Paintlia, Manjeet K ^a   Singh, Inderjit ^a   Skoff, Robert B ^b   Singh, Avtar K ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Demyelination; EAE MS; Inflammation

Indexed keywords

CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; MEVINOLIN; ONDANSETRON; PLACEBO; ROLIPRAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; NEUROPROTECTIVE AGENT; PHOSPHODIESTERASE INHIBITOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEMYELINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ELECTRON MICROSCOPY; ENZYME ACTIVATION; FEMALE; GROOMING; HEAD MOVEMENT; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE DEGENERATION; NERVE FIBER; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL; VOMITING; ANIMAL; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; LEWIS RAT; METABOLISM; MYELINATED NERVE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; CENTRAL NERVOUS SYSTEM; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; LOVASTATIN; NERVE FIBERS, MYELINATED; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED LEW; ROLIPRAM; TREATMENT OUTCOME; WALLERIAN DEGENERATION;

EID: 60549097585     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20745     Document Type: Article

References (65)

1. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278:1910-1914.
2. Arbizu T, Alvarez-Cermeno JC, Decap G, Fernandez O, Uria DF, Garcia Merino A, Izquierdo G, Montalban X. 2000. Interferon beta-1b treatment in patients with relapsing-remitting multiple sclerosis under a standardized protocol in Spain. Acta Neurol Scand 102:209-217.
3. Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJ, Stiles CD. 2004. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306:2111-2115.
4. Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55:458-468.
5. Besser M, Wank R. 1999. Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162:6303-6306.
6. Bielekova B, Lincoln A, McFarland H, Martin R. 2000. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 164:1117-1124.
7. Bjartmar C, Wujek JR, Trapp BD. 2003. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165-171.
8. Bolton S, Butt AM. 2006. Cyclic AMP-mediated regulation of the resting membrane potential in myelin-forming oligodendrocytes in the isolated intact rat optic nerve. Exp Neurol 202:36-43.
9. Brustle O, Jones KN, Learish RD, Karram K, Choudhary K, Wiestler OD, Duncan ID, McKay RD. 1999. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science 285: 754-756.
10. Cui Q, So KF. 2004. Involvement of cAMP in neuronal survival and axonal regeneration. Anat Sci Int 79:209-212.
11. Dhib-Jalbut S. 2003. Glatiramer acetate (Copaxone(R)) therapy for multiple sclerosis. Pharmacol Ther 98:245-255.
12. Dhib-Jalbut S, Chen M, Henschel K, Ford D, Costello K, Panitch H. 2002. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Mult Scler 8: 485-491.
13. Domeniconi M, Filbin MT. 2005. Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol Sci 233:43-47.
14. Echeverria V, Clerman A, Dore S. 2005. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci 22:2199-2206.
15. Eng LF, D'Amelio FE, Smith ME. 1989. Dissociation of GFAP intermediate filaments in EAE: Observations in the lumbar spinal cord. Glia 2:308-317.
16. Eralinna JP, Soilu-Hanninen M, Roytta M, Hukkanen V, Salmi AA, Salonen R. 1996. Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis. J Neuroimmunol 66:103-114.
17. Genain CP, Roberts T, Davis RL, Nguyen MH, Uccelli A, Faulds D, Li Y, Hedgpeth J, Hauser SL. 1995. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 92:3601-3605.
18. Giuliani F, Fu SA, Metz LM, Yong VW. 2005. Effective combination of minocycline and interferon-beta in a model of multiple sclerosis. J Neuroimmunol 165:83-91.
19. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. 2003. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. Faseb J 17:905-907.
20. Hanson MG Jr., Shen S, Wiemelt AP, McMorris FA, Barres BA. 1998. Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J Neurosci 18:7361-7371.
21. Holmberg E, Nordstrom T, Gross M, Kluge B, Zhang SX, Doolen S. 2006. Simvastatin promotes neurite outgrowth in the presence of inhibitory molecules found in central nervous system injury. J Neurotrauma 23:1366-1378.
22. Jeffery DR, Chepuri N, Durden D, Burdette J. 2005. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler 11:296-301.
23. Johnson-Anuna LN, Eckert GP, Franke C, Igbavboa U, Muller WE, Wood WG. 2007. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem 101:77-86.
24. Johnson-Anuna LN, Eckert GP, Keller JH, Igbavboa U, Franke C, Fechner T, Schubert-Zsilavecz M, Karas M, Muller WE, Wood WG. 2005. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312: 786-793.
25. Kirstein M, Farinas I. 2002. Sensing life: regulation of sensory neuron survival by neurotrophins. Cell Mol Life Sci 59:1787-1802.
26. Krause W, Kuhne G. 1988. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica 18:561-571.
27. Kwak B, Mulhaupt F, Veillard N, Pelli G, Mach F. 2001. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 131:41-46.
28. Lu D, Qu C, Goussev A, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M. 2007. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma 24:1132-1146.
29. Lublin FD. 1985. Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis. Springer Semin Immunopathol 8:197-208.
30. Luccarini I, Ballerini C, Biagioli T, Biamonte F, Bellucci A, Rosi MC, Grossi C, Massacesi L, Casamenti F. 2008. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. Exp Neurol 211:214-226.
31. Markovic-Plese S, McFarland HF. 2001. Immunopathogenesis of the multiple sclerosis lesion. Curr Neurol Neurosci Rep 1:257-262.
32. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. 2004. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015-2021.
33. Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP. 2007. Simvastatin regulates oligodendroglial process dynamics and survival. Glia 55:130-143.
34. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, Schwartz M. 2000. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun 15:331-345.
35. Nikulina E, Tidwell JL, Dai HN, Bregman BS, Filbin MT. 2004. The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery. Proc Natl Acad Sci USA 101:8786-8790.
36. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N Engl J Med 343:938-952.
37. O'Garra A, Steinman L, Gijbels K. 1997. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 9:872-883.
38. Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. 2005. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. Faseb J 19:1407-1421.
39. Paintlia AS, Paintlia MK, Singh AK, Singh I. 2008. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 73: 1381-1393.
40. Paintlia AS, Paintlia MK, Singh AK, Stanislaus R, Gilg AG, Barbosa E, Singh I. 2004. Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin. J Neurosci Res 77:63-81.
41. Paintlia AS, Paintlia MK, Singh I, Singh AK. 2006. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 169: 1012-1025.
42. Pannu R, Christie DK, Barbosa E, Singh I, Singh AK. 2007. Posttrauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 101:182-200.
43. Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dorr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, Zipp F. 2008. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 3:e1928.
44. Pender MP, Nguyen KB, Willenborg DO. 1989. Demyelination and early remyelination in experimental allergic encephalomyelitis passively transferred with myelin basic protein-sensitized lymphocytes in the Lewis rat. J Neuroimmunol 25:125-142.
45. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G, Galli R, Del Carro U, Amadio S, Bergami A, et al. 2003. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422:688-694.
46. Pooler AM, Xi SC, Wurtman RJ. 2006. The 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor pravastatin enhances neurite outgrowth in hippocampal neurons. J Neurochem 97:716-723.
47. Ransohoff RM, Howe CL, Rodriguez M. 2002. Growth factor treatment of demyelinating disease: at last, a leap into the light. Trends Immunol 23:512-516.
48. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, et al. 2006. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354:911-923.
49. Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, Garcia-Merino A. 2005. Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 168:13-20.
50. Schulz JG, Bosel J, Stoeckel M, Megow D, Dirnagl U, Endres M. 2004. HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem 89:24-32.
51. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A, et al. 1995. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1: 244-248.
52. Song HJ, Ming GL, Poo MM. 1997. cAMP-induced switching in turning direction of nerve growth cones. Nature 388:275-279.
53. Sorensen PS. 2003. The role of intravenous immunoglobulin in the treatment of multiple sclerosis. J Neurol Sci 206:123-130.
54. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C. 2002. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci 22: 9221-9227.
55. Stuve O, Youssef S, Weber MS, Nessler S, von Budingen HC, Hemmer B, Prod'homme T, Sobel RA, Steinman L, Zamvil SS. 2006. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J Clin Invest 116:1037-1044.
56. Torphy TJ, Undem BJ. 1991. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 46:512-523.
57. Tullman MJ, Lublin FD. 2005. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep 5:245-248.
58. Vanderlocht J, Hendriks JJ, Venken K, Stinissen P, Hellings N. 2006. Effects of IFN-beta, leptin and simvastatin on LIF secretion by T lymphocytes of MS patients and healthy controls. J Neuroimmunol 177:189-200.
59. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607-1608.
60. Wong B, Lumma WC, Smith AM, Sisko JT, Wright SD, Cai TQ. 2001. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 69: 959-962.
61. Wu H, Lu D, Jiang H, Xiong Y, Qu C, Li B, Mahmood A, Zhou D, Chopp M. 2008. Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. J Neurotrauma 25:130-139.
62. Wujek JR, Bjartmar C, Richer E, Ransohoff RM, Yu M, Tuohy VK, Trapp BD. 2002. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 61:23-32.
63. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, et al. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84.
64. Ytterberg C, Johansson S, Andersson M, Olsson D, Link H, Holmqvist LW, von Koch L. 2007. Combination therapy with interferon-beta and glatiramer acetate in multiple sclerosis. Acta Neurol Scand 116:96-99.
65. Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, Tanaka J. 2002. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 42:262-269.